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   Systematic review  
Metabolomics in Phenylketonuria disease: A 
systematic review 
Hadia Bakkali Aissaoui 
Resumen: La fenilcetonuria es una trastorno hereditario que es necesario diagnosticar correctamente durante 
los primeros años de vida. La metabolómica podría ser una buena herramienta para mejorar las técnicas 
usadas actualmente para detectar esta enfermedad identificando biomarcadores en muestras biológicas. El 
objetivo de esta revisión sistemática es proporcionar un resumen de los últimos avances conseguidos 
mediante la metabolomica en la identificación de biomarcadores de la fenilcetonuria. Se realizó una búsqueda 
sistemática de artículos publicados en bases de datos como PubMed y Web of Science hasta el mes de marzo 
del 2021. Los estudios se incluyeron solo si aplicaban técnicas utilizadas con la metabolómica para detectar 
biomarcadores en muestras humanas. Resultaron incluidas diez publicaciones en esta revisión y se 
identificaron 34 metabolitos relacionados con la fenilcetonuria. Varios metabolitos fueron identificados por 
diferentes estudios y se clasificaron como diferenciales com es la fenilalanina, el ácido fenilpirúvico, la 
arginina, la tirosina, la carnitina, la dimetilarginina asimétrica y el ácido docosahexaenoico. Mediante el 
Pathway Analysis se observó una mayor implicación del metabolismo de los amino ácidos en la fenilcetonuria. 
En esta revisión se resumieron los estudios metabolómicos publicados sobre biomarcadores de la 
fenilcetonuria. Además, se identificaron desregulaciones metabólicas que suceden en pacientes con 
fenilcetonuria. Se necesitan más estudios metabolómicos para comprender mejor todos los cambios 
metabólicos de la fenilcetonuria e identificar metabolitos diferenciales más significativos para mejorar el 
diagnóstico y el tratamiento nutricional. 
Abstract: Phenylketonuria is an inherited disorder with an important need to be diagnosed at early ages. 
Metabolomics could be an excellent tool to improve the actual techniques used to detect this disease by 
identifying biomarkers. The aim of this review is to provide a summary of the last advances achieved through 
metabolomics on the identification of phenylketonuria biomarkers. A systematic search was conducted using 
PubMed and Web of Science through February-March 2021. Studies were included only if metabolomics were 
applied and metabolomics technics were used to detect the biomarkers on human samples. At the end, ten 
publications were included in this review and 34 metabolites were identified to be related to phenylketonuria. 
Several metabolites were identified repeatedly and classified as differential metabolites of phenylketonuria, 
including phenylalanine, phenylpyruvic acid, arginine, tyrosine, carnitine, asymmetric dimethylarginine and 
docosahexaenoic acid. The pathway analysis showed a major implication of amino acids metabolism in 
phenylketonuria. In this systematic review, published metabolic studies on phenylketonuria biomarkers were 
summarized. Moreover, metabolic disorders in PKU patients were identified. More metabolomic studies are 
needed to better understand all metabolic changes of phenylketonuria and to identify more significant 
differential metabolites to improve the diagnosis. 
Keywords: phenylketonuria, metabolomics, dietary treatment, biomarkers 
Abbreviations: Phenylketonuria (PKU), phenylalanine (Phe), Tyrosine (Tyr), Tryptophan (Trp), Amino Acid 
(AA), asymmetric dimethylarginine (ADMA), hydroxykynurenic acid (3HK), homovanillic acid (HVA), 3-
methoxytyramine (3MT), 5-hydroxyindole acetic acid (5HT), kynurenic acid (KA) 
 
1. Introduction 
Phenylketonuria is a metabolic disorder caused by a mutation in the phenylalanine hydroxylase 
(PAH) gene. It is characterized by a phenylalanine (PHE) accumulation in plasma with decreased 
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tyrosine biosynthesis. Intellectual disability, motor deficits and psychiatric problems are some the 
possible effects of phenylketonuria [1]. Approximately, the worldwide prevalence of 
phenylketonuria (PKU) is 6,002 per 100,000 neonates [2], with Turkey being the country with the 
highest prevalence. An early detection is essential because newborns with PKU seem to be normal 
during the first days of life but over the months the disease starts to be more visible [2]. In this case, 
the diagnosis is based on the criteria established by the European Society for PKU and Allied 
disorders Treated as PKU [3]. 
 
For the management of PKU, the dietary treatment is the basis and it consists of following a diet 
with a protein restriction and supplemented with phenylalanine-free amino acid formula [4]. The 
restricted diet consists in avoiding food rich in protein and food and drinks containing aspartame 
flour or soya. Moreover, recently sapropterin (BH4) has been approved to treat PKU patients, 
especially the ones with high residual activity of phenylalanine hydroxylase (PAH), the responsible 
of converting Phe into L-tyrosine [3]. As seen in several publications, a correct supplementation of 
BH4 improves levels of some of the most important biological markers that suffer modifications in 
PKU patients [5,6].  
 
In this context, metabolomics is considered the omic approach that can best characterize the 
phenotypes of human beings. Metabolomics is used to study the metabolic products that can be 
found in biological samples. The objective of this discipline is to analyse the maximum number of 
metabolites and select those that truly provide information on the studied situation. Nowadays, it 
is possible to study unexpected metabolic pathways by using these metabolomic technologies [7]. 
In inborn metabolic errors, metabolomics has been used to improve diagnostic efficiency given the 
advances in the technology that is applied in this discipline [8]. Some of the improves that were 
recently implemented in PKU patients is the identification of profiles to urine samples so the 
adherence to the treatment could be well documented. Several studies used metabolomics analysis 
to determine differences in PKU patients metabolism and some alterations that were observed were 
in cholesterol concentrations, monoamines, vitamins and minerals, etc. [9,10]. 
 
The aim of this systematic review was to provide an overview of the published research on 
metabolomics technics being useful on improving phenylketonuria diagnosis. Namely, by 
identifying inherent phenylketonuria biomarkers and existing metabolic profiles in humans. 
Despite of the lack of evidence, having an overview of the current research might be practical for 
future applications improving the diagnostic for this metabolic disorder. One of the application of 
interest, related to metabolomics, is to treat different Inborn Errors of Metabolism by measuring 
secondary metabolites common in these to increase the efficiency of diagnosis [8]. In the future, 
having additional information, would be positive given that the single analyte for diagnosis could 
be amplified.  
2. Materials and Methods 
2.1. Search Strategy and Study Selection 
This systematic review was conducted using Pubmed (https://pubmed.ncbi.nlm.nih.gov/) and the 
Web of Science (https://apps-webofknowledge-com) databases in February 2021 using the syntaxes 
reported in Supplementary Table S1. 
Electronic searches were supplemented with manual searches of references from included studies 
and reviews on related topics. Studies were included in the present systematic review, if i) they 
were scientific findings on phenylketonuria using different metabolomics technics, ii) they were 
done with humans and not animals, iii) they provided information on differential metabolic 
markers, iv) if metabolomics technics were performed to analyse human samples (blood, feces or 
urine) v) dietary adherence or type of dietary management was recognized as a variable to study. 
Exclusion criteria included i) not reported in a European language. No restrictions for the 
characteristics of study participants (e.g., age, sex, weight, and other health conditions) were 
applied when selected. 
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2.2. Quality assessment  
 
The QUADOMICS [11], an adaptation of QUADAS [12], criterion was used to evaluate the 
methodological quality of the included studies. The criterion consists of 16-item scale which 
includes: inclusion and exclusion criteria, sample characteristics, differential conditions in 
preanalytical, clinical and physiological characteristics of research subjects, uninterpretable test 
results and the presence or avoidance of over-fitting. In this review, only the studies that fulfilled 
with 70% or more were included.  
2.4. Data extraction and pathway analysis 
Data were extracted from each identified study and the following information was collected: name 
of the authors, year of publication, number of participants/controls, dietary management that was 
controlled and if supplementation formula was used, levels of the metabolites that were studied, 
outcomes (phenylalanine levels, tyrosine levels, other diseases presented…), main findings. The 
pathway analysis resulted from including the metabolites from several biological sample 
implementing the MetaboAnalyst [13] software (version 5.0) on the basis of Kyoto Encyclopedia of 
Genes and Genomes and Human Metabolome Database. 
3. Results 
3.1. Study selection 
The study selection process that was done in this systematic review is shown in Figure 1 
specificizing all the phases and why the excluded articles were not included in our work. A total 
of 515 records were identified through the database search that was carried out in both PubMed 
and Web of Science databases. After removing 53 articles that were duplicated, 552 articles were 
screened and 502 were excluded based on the title or the abstract.  
A total of 50 eligible records went under the full text screening process. After this process we 
excluded 40 articles because they did not meet the inclusion criteria that was specified above.  
Ten articles met eligibility criteria, providing data on a total of 7 prospective cohorts and 3 cross-
sectional studies on patients with phenylketonuria (Figure 1).  
3.2. Quality of the Included Studies 
All the studies that were evaluated using the QUADOMICS tool were phase I, all of these used 
tests to identify patients or cases with one specific disease from healthy controls [11]. All the results 
are shown in Supplementary Table S2. Only studies that identified differential and remarkable 
metabolites were included. Seven studies met the criteria of including in detail the inclusion and 
exclusion criteria, sources of samples and a comparison between the included and excluded patient 
[14–20]. The item 14 was not applied to either of the included studies because it only applies to 
studies of phase IV [11]. All the ten included studies described the index test in sufficient detail to 
permit replication of the test or mentioned the guidelines or studies previous to the publication of 
the recommendations that were followed. 
3.3. Characteristics of the Included Studies 
The main characteristics of the included studies are reported in Table 1. Out of the 10 included 
articles, 9 of them characterized or determinated levels of specific metabolites in PKU patients 
following a restricted diet, with or without supplementation. The remaining 2 publications [18,20] 
investigated specific relations like docosahexaenoic acid status in PKU patients following a 
restricted diet and cognitive performance and the other one studied the possible modifications in 
tryptophan pathways when a phe-restricted diet is followed. Most of the articles were performed 
in Germany (n=4), followed by Spain and France (n=3), the United States of America (n=2) and 
Canada (n=1). 
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Figure 1. Flow diagram of literature search and study selection for metabolomics and phenylketonuria. 
Legend: WOS: Web of Science 
 
Patients with Phenylketonuria must follow a phenylalanine restricted diet or a protein restricted 
diet. From the selected articles, 8 clearly mentioned that a certain percentage of the patients 
participating in the study were following a special restricted diet [14–19,21,22]. One publication 
just mentioned that a classical and strict dietary treatment was followed. About the remaining 
study, it does not mention what type of treatment the patients were receiving [23]. The number of 
study participants ranged from n= 12 [22] to n=151 [19], while mean age ranged from 1 [18] to 54 
years [14]. 
 
A Phe-free amino acid formula is also part of the dietary treatment for PKU patients. In the 
included studies, 5 articles [14,16,19,20,22] had PKU patients with amino acid supplementation 
devoid of Phe but enriched in tyrosine and other essential aa. Two studies [15,18] had PKU patients 
with a restricted diet but also with sapropterin (BH4) as supplementation. Vilaseca et al. [18] 
included the phe-free amino acid formula in the treatment too. And the remaining two studies 
[21,23] did not mention if a supplementation was prescribed as part of the dietary treatment of the 
PKU participants. 
 
In relation with the type of biological sample that was used to identify metabolic markers, 7 studies 
[14,17–22] applied metabolomic technics in plasma samples of PKU patients, 2 studies [15,23] used 
urine samples and the remaining 2 publication [15,16] used both urine and plasma samples to 
analyze different metabolites.  
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Table 1. Characteristics of the included studies investigating on metabolomics and the disease of phenylketonuria.  
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3.4. Metabolites Identified for Phenylketonuria 
Metabolomics technics are used to identify and characterize phenylketonuria metabolic biomarkers. 
Several publications study and compare the sensitivity and specificity of some of the conventional 
technics [24–27]. A multiplatform approach is preferred to analyse the metabolome profile [28]. Thus, 
the involvement of different pathophysiological processes could be confirmed as a system that hap-
pens in every PKU patient’s metabolism. Nevertheless, most of the included studies used one technic 
like high-performance liquid chromatography (HPLC) that is used with several modifications. Doug-
las, et al. used HPLC with electrochemical detection to study plasma amino acids and other metabo-
lites. Vilaseca et al. [18] applied HPLC with UV detection in their study and Andrade et al. and Boulet 
et al. [19,21] used it coupled to mass spectrometry. Only one of the included articles used Nuclear 
magnetic resonance (NRM) technic [14].  
 
Mütze et al. applied liquid chromatographic tandem mass spectrometry (LC-MS/MS) to analyse the 
influence of moderate long-term fatty acids restriction in PKU patients and gas chromatography to 
determine the fatty acid composition of plasma glycerophospholipids [22]. Wild, et al. [20] carried on 
a urine metabolite profiling by MSI-CE-MS which resulted to offer a valuable analytical tool for dieti-
tians to better monitor phenylalanine intoxication due to poor dietary adherence in PKU patients. 
About the others included studies [16–18,23] used Gas Chromatography coupled to Mass Spectrome-
try (GC/MS) to obtain metabolomic information. Xiong and colleagues used an improved oximation-
silylation method combined with GC/MS and based on the results they concluded that this improved 
technique might be reliable for the diagnosis and differential diagnosis of PKU [23].  
 
In total, 34 differential metabolites were extracted from the 10 included publications in this review. 
Based on the number of times the metabolites were reported, phenylalanine, arginine and carnitine 
are the most significant metabolites because they were reported up to three times [16–18,20–22] fol-
lowed by phenylpyruvic acid, asymmetric dimethylarginine (ADMA) and docosahexaenoic acid, 
which were reported two times [16–18,20,21,23]. Seven high frequency (reported twice or more) dif-
ferential metabolites were identified which are displayed in Table 2.  
Table 2. High Frequency Differential Metabolites Related to Phenylketonuria. 
Metabolite Name  HMDB ID Hits  Biological samples  
Phenylalanine HMDB0000159 3 Plasma  
Arginine HMDB0000517 3  Plasma 
Carnitine  HMDB0000062 3 Plasma 
Phenylpyruvic acid HMDB0000205 2 Urine 
Tyrosine  HMDB0000158 2 Plasma 
ADMA HMDB0001539 2 Urine 
DHA HMDB0002183 2 Plasma 
ADMA: asymmetric dimethylarginine; DHA: Docosahexaenoic acid, HMDB ID: The Human Metabo-
lome Database 
 
Phenylpyruvic acid was determined as the most significant urinary biomarker by two studies [20,23]. 
Additionally, Wild et al. detected low levels in plasma and urine samples of arginine, tyrosine, 2-
aminobutyric acid, propionylcarnitine, 2-aminoadipic acid, aminohippuric acid, urocanic acid and 
carnitine. Contrary, elevated levels of phenylacetylglutamine, hydroxyphenylacetic, imidazole lactic 
acid and phenylpyruvic acid were found in plasma of PKU patients [20]. Xiong, et al. [23] identified 
phenylacetic acid as a possible reliable discriminator for the diagnosis of PKU. This was determined 
with the largest area under the curve (AUC) of 0,987, and a high specificity and sensitivity of 0,936 
and 1.000, respectively. Furthermore, 19 differentially compounds were reported in PKU patients such 
as phenylpyruvic acid, 2-hydroxyphenylacetic acid and N-phenylacetylglutamine [23].  




The decreasing of DHA, asymmetric dimethylarginine (ADMA), Hcys, carnitine, acylcarnitine, Tyr, 
glutamine, hydroxykynurenic acid (3HK) and the increasing of homovanillic acid (HVA), 3-methox-
ytyramine (3MT), 5-hydroxyindole acetic acid (5HT), serotonin, kynurenic acid (KA) and KYN were 
observed in several publications included in this review.  
3.5. Pathway analysis 
The metabolomic information of 10 studies on phenylketonuria [14–23] were integrated to study en-
riched pathways and impact pathways at the significance level of 0.05 on both p value and FDR 
(False Discovery Race). In Table 3 and 4, those pathways are shown with also the impact and the 
match status of each one.  




P value FDR Impact 
Phenylalanine metabolism  5/10 7,48E-7 6,28E-5 0,619 
Phenylalanine, tyrosine and tryptophan 
biosynthesis 
3/4 3.472E-5 0.0015 1.0 
Tyrosine metabolism  4/42 0.0108 0.3018 0.287 
Aminoacyl-tRNA biosynthesis  4/48 0.0171 0.34 0.0 
Cysteine and methionine metabolism  3/33 0.0310 0.467 0.233 
Arginine biosynthesis  2/14 0.0341 0.467 0.076 
Biosynthesis of unsaturated fatty acids  3/36 0.039 0.467 0.0 
Tryptophan metabolism  3/41 0.0541 0.568 0.213 
Thirty-four differential metabolites, which were reported in plasma and urine, were included in the 
software MetaboAnalyst for pathway analysis and enrichment analysis. A visual graphic was created 
with metabolic signatures related to the phenylketonuria metabolites that were integrated in this anal-
ysis (Figure 2).  
When significance is determined by both p value and FDR for the pathways, phenylalanine metabo-
lism and phenylalanine, tyrosine and tryptophan biosynthesis were significantly enriched from the 
resulted pathways reported in plasma (Table 3). 




       
 Figure 2. Pathway analysis for significant metabolites of PKU  
 
4. Discussion 
In this systematic review, we analyzed 10 studies and determined significant metabolic pathways of 
phenylketonuria by conducting a Pathway Analysis with MetaboAnalyst software. As a result of this 
analysis, seven differential metabolites were identified in two studies or more and were determined 
as high frequency metabolites in PKU. Phenylalanine is the most remarkable, reliable and promising 
metabolic marker with the highest intervention in most identified metabolic pathways. Due to the 
significant enriched metabolism pathways found in the conducted analysis, metabolic dysregulations 
could be more studied in phenylketonuria patients for a better understanding of the disorder. 
 
4.1. Dietary Treatment on PKU and Metabolomics application  
 
Metabolomics technics were used in the included studies to determine differential metabolites in PKU 
patients based on the concentrations found in urine and plasma. The concentration of monoamines is 
an important deficiency that appear in patients with a restricted diet as mentioned by several studies 
[9,29,30]. Douglas et al. [15] studied the impact of sapropterin on monoamine neurotransmissor status 
in patients with PKU between 4 to 49 years old with a restricted diet and supplementation of saprop-
terin (20mg/kg/day). They concluded that the degree of adherence to dietary Phe restriction had no 
significant correlation with monoamine outcomes but with the medical food that was facilitated to 
patients [15]. 
 
Several publications [14,18,22] studied the fatty acid profile in PKU patients following a restricted diet 
with medical food treatment. Cannet et al. [14]. found that a good adherence was correlated with Phe 
levels. Two publications [17,18] observed lower concentrations of docosahexaenoic acid (DHA) in 
PKU patients. However, lower concentrations of DHA are shown due to the restriction of LCPUFA 
sources in Phenylketonuria restricted diet. Some of these principles sources are fish, meat, eggs, nuts, 
liver, or milk products [31]. Tough, no improvement was seen when some animal fat and a few por-
tions of yogurt and quail egg yolk were included [18], which means DHA concentrations cannot be 
improved by only dietary treatment. Another study evaluated metabolic pathways of fatty acids in 
PKU patients and reduced concentrations of acylcarnitine and others intermediates were found [22].  




Furthermore, Boulet, et al. [19] studied the tryptophan metabolism in a cohort of 151 PKU patients 
and how it is modified when a controlled low Phe diet was followed. Tryptophan is an essential AA 
involved in protein synthesis, a precursor of serotonin and others active substances [32]. They found 
that concentrations of hydroxykynurenic acid (3HK), a tryptophan metabolite, was lower in only pa-
tients that underwent controlled low Phe-diet, but this could be restored when a Phe-free amino acid 
substitute was taken[19].  
 
Given that low asymmetric dimethylarginine (ADMA) levels have been observed in adolescents and 
adults with PKU, most of the evidence refers to a possible cardiovascular risk in PKU patients [33]. 
Kanzelmeyer, et al. [16] found that the concentrations of the ADMA, an endogenous inhibitor of nitric 
acid and a novel marker of cardiovascular risk, is unaltered in PKU patients. Despite of ADMA con-
centrations were unaltered they came to be lower in PKU patients than in the control group [21]. In 
this present study, homocysteine (Hycs) levels were lower than normal range and it was due to the 
low-quality protein intake that PKU patients follow because of the disease. 
 
Metabolomics could be used to improve the diagnosis of phenylketonuria by detecting more differ-
ential metabolites in biological samples.  
 
4.2. Metabolic Dysregulations Implicated in Phenylketonuria Pathogenic Mechanisms 
 
By the obtained results of the different pathways, amino acid dysregulation was the most notable 
characteristic of phenylketonuria metabolic pathways. Phenylalanine resulted to be an important bi-
omarker in the pathways of phenylalanine, tyrosine and tryptophan. Moreover, a relation was indi-
cated between these metabolites because phenylalanine dietary intake can influence in both phenyl-
alanine hydroxylation and tyrosine oxidation as well as at the rates of plasma phenylalanine and ty-
rosine concentrations [34]. 
 
High Phe concentrations are due to a less strict compliments of the diet and this can result in a range 
of neuropsychiatric problems like depression and anxiety [35]. Furthermore, different type of cogni-
tive dysfunction in PKU patients were hypothesized to be related to elevated blood Phe concentrations 
or reduced blood Tyr concentrations [36]. Some reports have already characterized the role of Phe in 
the deficiencies of several precursors of monoamine neurotransmitters, as Tyr and Trp. This happens 
due to the competitive inhibition from Phe for the large neutral amino acid (LNAA) transporter 1 
(LAT1) [36,37]. Likewise, tyrosine was also identified as a high frequency biomarker in phenylketonu-
ria. Tyrosine is a non-essential amino acid that is synthesized from phenylalanine. But, since PKU 
patients cannot synthesize Tyr from Phe on account of the sever deficiency of PAH enzyme, Tyr is 
considered as an essential amino acid in these patients [34].  
 
Tryptophan metabolism was also shown to be crucial for the development of phenylketonuria as an 
essential amino acid involved in protein synthesis and a substrate to serotonin synthesis [32]. Trypto-
phan also has a role as the precursor of an active substance called kynurenine (KYN), this metabolite 
was also identified in PKU patients biological samples in lower levels than normal [19]. Furthermore, 
tryptophan metabolism is linked with neurological perturbation, which several PKU patients suffer 
when there is not a good adherence to dietary treatment and supplementation [1]. Tryptophan metab-
olism is considered important in phenylketonuria because several similarities are presented between 
both metabolic pathways of phenylalanine and tryptophan. For example, both amino acid use the 
same L-large neutral amino acid type 1 transporter to cerebrospinal fluid, and this has an affinity 
stronger to Phe than to Trp [38,39]. 
 
4.3. The role of metabolomics in clinical implications of Phenylketonuria  
 
Following a restricted diet on animal protein a low cholesterol concentration might be found in blood. 
This, being known to be a protector effect on cardiovascular diseases such as atherosclerosis. 
Universitat de Barcelona, 20 11 of 16 
 
 
Although, it doesn’t apply to several PKU patients because of having elevated levels of ADMA, a 
metabolic by-product from protein metabolism found in blood [44].  
 
One of the main metabolites that could be a cardiovascular risk if was found in high levels is ADMA. 
This tends to happen with homocystinuria, which is presented in several PKU patients. Kanzelmeyer 
et al. implemented a MS technique to find that the levels of ADMA were lower in PKU patients than 
in controls. Consequently, it should not be considered a risk and it may be due to the decreased nitric 
oxide (NO) synthesis, an endogenous vasodilator, or other pathways [16].  
 
Furthermore, when a restricted diet is followed a nutrient deficiency can occur and then an oral sup-
plementation might be necessary. In PKU patients a Phe free amino acids supplementation is pre-
scribed. Though, it should be considered that these formulas may suffer from oxidation, and conse-
quently these amino acids would not be efficient enough [21]. Thus, it is important to evaluate first if 
patients are good responders to such supplementation and if not, other options should be considered.   
 
Tetrahydrobiopterin (BH4), also known as sapropterin, is used along with the restricted diet to control 
blood Phe levels in adults and children with 1 month of age and older with PKU [45]. Vilaseca, et al. 
found that DHA levels were normal in PKU patients treated with BH4[18]. Douglas, et al. studied the 
effects of sapropterin on urinary monoamines using metabolomics techniques to identify modifica-
tions in differential metabolites. Homovanillic acid (HVA), a marker of dopaminergic activity, was 
increased in PKU patients after 1 month of sapropterin (20mg/kg) [15].  
5. Conclusions 
 
The findings in this review on 34 high-frequency metabolites have been indicated to be in relation 
with Phenylketonuria. The noted metabolic pathways may provide a better understanding of all the 
implicated biological mechanisms of the disease. Metabolomics approach could be used to determine 
more differential metabolites to improve the diagnosis and treatment.  
 
Due to the vast majority of studies being conducted in small cohorts with limited number of partici-
pants, generalizability and applicability are limited. Furthermore, considering the wide variability in 
terms of study design, technics, methods of outcome assessment there is limitations of the compara-
bility of these studies. From all the studies selected studies, we could see that is not difficult to study 
PKU metabolites in patients that present nutritional deficiencies and that need to be guided by a pre-
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Supplementary Table S2 Methodological quality assessment using the QUADOMICS Tool. 
Table 1. Used items are described in the next list.  
1. Were selection criteria clearly described? 
2. Was the spectrum of patients representative of patients who will receive the test in practice?  
3. Was the type of sample fully described? 
4. Were the procedures and timing of biological sample collection with respect to clinical factors described 
with enough detail? 4a. Clinical and physiological factors 4b. Diagnostic and treatment procedures 
5. Were handling and pre-analytical procedures reported in sufficient detail and similar for the whole sam-
ple? And, if differences in procedures were reported, was their effect on the results assessed?  
6. Is the time period, between the reference standard and the index test short enough to guarantee that the 
target condition did not change between the two tests? 
7. Is the reference standard likely to correctly classify the target condition?  
8. Did the whole sample or a random selection of the sample receive verification using a reference standard 
of diagnosis?  
9. Did patients receive the same reference standard regardless of the result of the index test?  
10. Was the execution of the index test described in sufficient detail to permit replication of the test? 
11. Was the execution of the reference standard described in sufficient detail to permit its replication?  
12. Were the index test results interpreted without knowledge of the results of the reference standard?  
13. Were the reference standard results interpreted without knowledge of the results of the index test?  
14. Were the same clinical data available when test results were interpreted as would be available when the 
test is used in practice?  
15. Were uninterpretable / intermediate test results reported?  
16. Is it likely that the presence of over-fitting was avoided; Y=criteria achieved, N=criteria not achieved, 
N/A=not applicable. 
Y=criteria achieved, N=criteria not achieved, N/A=not applicable. 
Ref. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 score 
Cannet (2020) Y N/A Y Y Y Y Y Y Y Y Y N Y N/A N N 11/13 
Douglas (2013) Y N/A Y Y Y Y Y Y Y Y Y N Y N/A N Y 12/13 
Kanzelmeyer (2012) Y N/A Y Y Y Y Y Y Y Y Y N Y N/A N N 11/13 
Yi (2011) Y N/A Y Y Y Y Y Y Y Y Y N Y N/A N Y 12/13 
Vilaseca (2010) Y N/A Y Y Y Y Y Y Y Y Y N Y N/A N N 11/13 
Boulet (2020) Y N/A Y Y Y Y Y Y Y Y Y N Y N/A N N 11/13 
Wild (2019) Y N/A Y Y Y Y Y Y Y Y Y N Y N/A N Y 12/13 
Andrade (2017) N N/A Y Y Y Y Y Y Y Y Y N Y N/A N Y 11/13 
Mütze (2012) N N/A Y Y Y Y Y Y Y Y Y N Y N/A N Y 11/13 
Xiong (2015) N N/A Y Y Y Y Y N/A N/A Y Y N Y N/A N Y 9/12 
